Sacituzumab Govitecan

Buy Sacituzumab Govitecan in India
Generic Name/API:Sacituzumab govitecan
Packaging:180 mg in 1 vial per pack
Storage:Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F)
Dosage:For injection: 180 mg off-white to yellowish lyophilized powder in a single-dose vial.
Strength:180 mg
Indication:Trodelvy® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate used to treat metastatic triple-negative and HR+/HER2- breast cancers in adults who have received prior therapies. It delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing tumor cells, blocking DNA replication and causing cell death.

Trodelvy® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate that delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing cancer cells. It treats adults with metastatic triple-negative breast cancer (TNBC) after two or more prior therapies, and HR+/HER2- metastatic breast cancer after endocrine and systemic therapies. It’s also used for locally advanced or metastatic urothelial cancer post-platinum and PD-1/PD-L1 inhibitor treatment.

STRENGTH 

For injection: 180 mg off-white to yellowish lyophilized powder in a single-dose vial. 

DOSAGE

  • The recommended dosage is 10 mg/kg administered, only as an intravenous infusion, once weekly on days 1 and 8 of 21 day treatment cycles. 
  • Continue treatment until disease progression or unacceptable toxicity. 
  • No dose higher than 10 mg/kg is recommended.  
  • First infusion is administered over 3 hours. Continuous monitoring during and 30 minutes post infusion for infusion-related reactions is advised. 
  • For subsequent infusions, administration over 1 to 2 hours, given no reactions to previous infusions, and observation during and 30 mins post infusion.

SIDE EFFECTS 

Following are the side effects of trodelvy treatment:  

  •  Neutropenia
  •  Diarrhea
  •  Hypersensitivity and Infusion-Related Reactions 
  • Nausea and Vomiting 

STORAGE 

  • Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution. 
  • Do not freeze.

  1. Neutropenia (reported in 61% patients undergoing trodelvy infusion)

Neutropenia of severe, life threatening or fatal grade observed in patients treated with trodelvy. Treatment must be withheld for neutropenic fever and for neutropenia, wait till neutrophil count drops below 1500 per mm3 on Day 1 of any cycle or below 1000 per mm3 on Day 8 of any cycle.

  1. Diarrhea (reported in 65% patients receiving treatment )

This treatment may cause severe diarrhoea. Withhold treatment in case of Grade 3 or 4 and resume on resolution till Grade 1 or below level of symptoms.. Excessive cholinergic response, in addition to diarrhea, consisting of abdominal cramping, salivation may be given medication like atropine for further treatments.

  1. Hypersensitivity and infusion-related reactions

Serious anaphylactic reactions, including those potentially life threatening, along with cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis and dermatological reactions. Hypersensitivity reactions can be avoided with premedication, and prepared emergency equipment.

  1. Nausea and vomiting (66% and 39% respectively)

Due to emetogenic properties, premedicate patients with 2 or 3 drug combinations regimen like dexamethasone+5-HT3 receptor antagonist/NK1 receptor antagonist. Withhold treatment and resume on resolution of symptoms, with additional measures like antiemetics and take home medications.

  1. Increased risk of adverse reactions in patients with reduced UGT1A1 activity

Patients who exhibit homozygosity for uridine diphosphate-glucuronosyltransferase 1A1 *28 allele have an increased chance of neutropenia, febrile neutropenia and anemia, as well as other adverse reactions. Such patients are to be closely monitored and treatment may be withheld or permanently stopped based on clinical assessment of the patient’s manifestations.

  1. Embryo fetal toxicity

Sacitizumab govitecan-hiiy can cause teratogenicity and /or embryo fetal lethality, genotoxicity in pregnant women undergoing treatment due to components like SN-38.

FAQ

Sacituzumab govitecan, marketed under the brand name Trodelvy, is an antibody-drug conjugate used to treat certain types of breast cancer. It combines an antibody that targets Trop-2 with a cytotoxic agent designed to help destroy cancer cells. Treatment suitability depends on the patient’s diagnosis, previous treatments, and applicable prescribing guidance.

Sacituzumab Govitecan is used for specific types of unresectable or metastatic breast cancer, including certain cases of triple-negative breast cancer (TNBC) and hormone receptor-positive, HER2-negative breast cancer. Eligibility depends on the applicable approved indication, previous treatments, and the treating oncologist’s assessment.

Sacituzumab Govitecan is administered by intravenous infusion under the supervision of a qualified healthcare professional. The dose and treatment schedule depend on the prescribed regimen and the patient’s clinical condition. Patients should follow their oncologist’s instructions and the applicable prescribing information.

Common side effects of Trodelvy may include diarrhoea, nausea, fatigue, neutropenia, anaemia, vomiting, hair loss, and decreased appetite. Serious adverse reactions can also occur, including severe neutropenia and diarrhoea. Patients should promptly inform their healthcare team about concerning symptoms and follow the monitoring and management instructions provided by their treating clinician.

The price of sacituzumab govitecan (Trodelvy) in India may vary depending on international sourcing, product availability, currency exchange rates (USD/EUR), and applicable import duties and charges. As the medicine may need to be imported, the final cost can change over time. For current pricing and availability information, please contact 24/7QualityMeds.

The availability of  Trodelvy (Sacituzumab Govitecan) in India may depend on current product availability, sourcing arrangements, and applicable import and regulatory requirements. If the medicine is not locally available, access may require an appropriate import pathway. Patients and healthcare professionals can contact 24/7QualityMeds to enquire about current availability and the applicable requirements.

Accessing sacituzumab govitecan through an import pathway may require a valid prescription, relevant medical documentation, and patient or importer details, depending on the applicable regulations. Additional documents may be required based on the case and the import process. The required documentation should be confirmed before proceeding.

Patients, caregivers, and healthcare professionals can contact 24/7QualityMeds at +91-9967979080 to enquire about sacituzumab govitecan (Trodelvy), including current availability, sourcing options, and applicable import requirements. Prescription-related and medical documentation may be required for assessment. Access is subject to product availability and applicable regulatory requirements.

Patients and healthcare professionals looking to buy Trodelvy (sacituzumab govitecan) in India can contact 24/7QualityMeds to enquire about product sourcing, current availability, and the applicable import process. As the medicine may require international sourcing, access depends on prescription requirements, individual circumstances, and applicable regulatory conditions.

For enquiries about buying Trodelvy in Mumbai, patients and healthcare professionals can contact 24/7QualityMeds to discuss potential sourcing options and the documentation required for assessment. If the medicine is not locally available, import may be considered through an applicable pathway, subject to regulatory requirements and product availability.

Patients and healthcare professionals looking to buy sacituzumab govitecan (Trodelvy) in Delhi can contact 24/7QualityMeds to enquire about product availability and the steps involved in assessing a sourcing request. Relevant prescription and medical documentation may be required to determine the applicable import requirements and potential access options.

Related products